Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: web + 0.19  Related to the article below (Last Update: 8/4/2008)

Web.com Reports Second Quarter 2008 Financial Results
istockAnalyst.com, OR -
"Despite challenging economic conditions, Web.com was able to hit the top of its quarterly revenue and earnings guidance. The operating leverage potential ...
APAC Customer Services Announces Second Quarter 2008 Results MarketWatch
all 70 news articles »  APAC
Ubuntu Security Notice - devhelp, epiphany-browser, midbrowser ...
Help Net Security, Croatia -
The problem can be corrected by upgrading your system to the following package versions: Ubuntu 8.04 LTS: devhelp 0.19-1ubuntu1.8.04.3 epiphany-gecko ...
Altra Holdings Announces Record Financial Results for the Second ...
MarketWatch -
Also, the company has posted slides on its web site at http://www.altramotion.com in the Investor Relations Section in the Events & Presentations tab to ...AIMC
FMC Corporation Announces Second Quarter 2008 Results
MarketWatch - Jul 29, 2008
This event will be available live and as a replay on the web at http://www.fmc.com. Prior to the conference call, the Company will also provide supplemental ...FMC

Earthtimes (press release)
McAfee, Inc. Reports 26 Percent Growth on Record Revenue of $397 ...
MarketWatch - Jul 31, 2008
McAfee Secure Search Service, delivering one of the safest online search experiences for consumers, and McAfee SECURE(TM) for Web Sites, ...
Stratasys Reports Record Second Quarter Financial Results Trading Markets (press release)
Sonic Foundry Reports Third Quarter 2008 Results IT News Online
Amgen's Second Quarter 2008 Adjusted Earnings Per Share Increased ... Trading Markets (press release)
MarketWatch
all 1,378 news articles »  MFE - EFII - SOFO
Firefox 3 chipping away Safari market share, summer browsing ...
TG Daily - Aug 1, 2008
For instance, on June 1 0.19% of users were browsing the web using an iPhone. Following June 11, when the iPhone 3G was introduced, that share increased to ...
Xantrex(TM) Technology Inc. Reports 2008 Second Quarter
MarketWatch - Jul 29, 2008
Our complete second quarter 2008 Management's Discussion and Analysis and Financial Statements are available on the Xantrex web site at www.xantrex.com. ...TSE:XTX - TPO:5468 - OTC:CMTX

WELT ONLINE
Susquehanna Bancshares, Inc. Announces Second Quarter Results
WELT ONLINE, Germany - Jul 23, 2008
Investors will have the opportunity to listen to the conference call through a live broadcast on Susquehanna?s Web site. The event may be accessed by ...
Columbia Bancorp Releases Second Quarter Financial Results ... FOXBusiness
TriCo Bancshares Announces Quarterly Earnings MarketWatch
Cascade Bancorp (Oregon) Announces Second Quarter 2008 Net Income ... MSN Money
Primenewswire (press release) - MarketWatch
all 1,034 news articles »  SUSQ - FSGI - TCBK
Dominion Announces Second-Quarter 2008 Earnings
Earthtimes (press release), UK - Jul 31, 2008
4) Refer to schedules 2 and 3 for details related to items excluded from operating earnings, or find "GAAP Reconciliation" on Dominion's Web site at ...D
Qualcomm Announces Third Quarter Fiscal 2008 Results
FOXBusiness - Jul 23, 2008
Prior period reconciliations are presented on Qualcomm's Investor Relations web page at www.qualcomm.com. "We are pleased to report another strong quarter ...QCOM
Source: Google News

Web caching and Zipf-like distributions: evidence and implications -
L Breslau, P Cao, L Fan, G Phillips, S Shenker - INFOCOM'99. Eighteenth Annual Joint Conference of the IEEE …, 1999 - ieeexplore.ieee.org
... Questnet NLANR L0.04 -0.08 0.003 -0.04 -0.02 -0.09 DEC UPisa FuNet UCB Questnet
NLANR -0.19 -0.27 0.005 0.002 -0.03 -0.08 the total number of web documents, q ...

Predicting the use of web-based information systems: self-efficacy, enjoyment, learning goal … -
MY Yi, Y Hwang - International Journal of Human-Computer Studies, 2003 - Elsevier
... d. ability to use favorite Web site 0.19 0.78 0.31 0.56 0.12 0.20 0.29 3.
Enjoyment a. have fun using0.11 0.24 0.95 0.46 0.48 0.47 0.07 ...

Measuring web site quality improvements: a case study of the forum on strategic management knowledge … -
SJ Barnes, R Vidgen - Industrial Management & Data Systems, 2003 - emeraldinsight.com
... 1.63 18 Conveys a sense of community 4.35 0.19 1.51 3.67 0.22 1.70 4.59 0.24 ... 0.21
1.66 5.10 0.17 1.32 4.95 0.18 1.37 20 What is your overall view of this Web

Measuring the Independence of Central Banks and Its Effect on Policy Outcomes -
A Cukierman, SB Web, B Neyapti - The World Bank Economic Review, 1992 - World Bank
Page 1. THE WORLD BANK ECONOMIC REVIEW. VOL. 6. NO. 1: 35J-J9J Measuring the
Independence of Central Banks and Its Effect on Policy Outcomes ...

Contact Sex Signals on Web and Cuticle of Tegenaria atrica (Araneae, Agelenidae) -
O Prouvost, M Trabalon, M Papke, S Schulz - Archives of Insect Biochemistry and Physiology, 1999 - doi.wiley.com
... Receptive females Unreceptive females Determination Web Cuticle Web Cuticle ... Esters
Methyl tetradecanoate (myristate) 0.19 (0.05) 0.55 (0.11)* ...

The detrital food web in a shortgrass prairie -
HW Hunt, DC Coleman, ER Ingham, RE Ingham, ET … - Biology and Fertility of Soils, 1987 - Springer
... HW Hunt et al.: The detrital food web in a shortgrass prairie ... 0.8 0.8 0.00058 0.56
0.19 0.8 0.8 0.0020 0.56 0.10 0.8 1.0 0.0020 0.56 0.10 0.5 0.8 0.021 0.56 ...

User Control and Structural Isomorphism or Disorientation and Cognitive Load?: Learning From the Web … -
WP EVELAND JR, S DUNWOODY - Communication Research, 2001 - crx.sagepub.com
... Web expertise 23.97 1 23.97 4.85 0.19 .03 .026 Cognitive load 43.48 1 43.48 8.80
?0.16 .00 .046 ... Web expertise 22.45 1 22.45 5.60 0.19 .02 .030 ...

[PDF] Removal policies in network caches for world-wide web documents -
S Williams, M Abrams, CR Strandridge, G Abdulla, E … - Computer Communication Review, 1996 - cs.kent.edu
... in networks with workloads like ours could dramat- ically reduce the load on popular
Web servers. ... Video 0.19 18.29 0.35 25.77 0.34 39.15 0.00 0.04 0.04 3.58 ...
-

Regulation of Lake Primary Productivity by Food Web Structure -
SR Carpenter, JF Kitchell, JR Hodgson, PA Cochran, … - Ecology, 1987 - JSTOR
... December 1987 LAKE PRODUCTIVITY AND FOOD WEB STRUCTURE 1869 0.6-- 0.4- 0.2- 0 6-
4- 1984 I ... SE -- 0.47, n = 13) in 1984 to 1.14 x 106/um3/mL (SE = 0.19, n = 13 ...

The development of two tools for measuring the easiness and usefulness of transactional Web sites -
AM Aladwani - European Journal of Information Systems, 2002 - ingentaconnect.com
... Table 5 Factor analysis results for Web site easiness & usefulness?holdout sample ...
Ease of finding the site 0.21 0.03 0.19 0.05 0.21 0.04 0.88 ...

Source: Google Scholar
 
 

Novel Protein Constructs Active Against Lymphoma In Animal Models

Article Date: 11 Dec 2006 - 0:00am (PST)
Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company focused on developing monoclonal antibodies, today announced the development of new multivalent antibodies against the CD20 and CD22 antigens present on normal and malignant B- lymphocytes, which showed activities against B-cell lymphomas in tissue culture and in animal models. Results on these next-generation protein constructs were presented in two posters at the 48th Annual Meeting of ASH in Orlando, FL.

The first poster presentation described the characterization of a bispecific antibody (bsMAb) composed of an intact humanized anti-CD20 antibody, hA20, linked to two single-chain variable fragments (scFvs) of an anti-CD22 antibody, epratuzumab. Thus, this fusion protein is tetravalent with 4 binding sites, two for CD20 and two for CD22. This tetravalent bsMAb was found to have anti-lymphoma activity similar to either hA20 or epratuzumab in vitro. The studies further demonstrated that the CD20/CD22 bsMAb has a mode of action against B-lymphoma cells distinct from that of either hA20 or epratuzumab. More importantly, the tetravalent bsMAb was more effective in improving the survival of mice bearing human lymphomas, when compared with its parental antibodies, hA20 or epratuzumab.

In a second poster presentation, multiple hexavalent antibodies were constructed using the Company's proprietary protein engineering platform technology called the Dock-and-Lock methodology (DNL) by linking an intact hA20 or epratuzumab to two antigen binding antibody fragments (Fabs) of hA20 or epratuzumab.

Article continues below and (thank you)
 
The resulting proteins: CD20/CD22 bsMAbs, hexavalent hA20, and hexavalent epratuzumab, each contain 6 binding arms. In cell cultures of human B-lymphoma cells, the hexavalent CD20/CD22 bispecific antibody constructs proved to be 100-times more potent in inhibiting growth than rituximab, while the hexavalent hA20 antibody was even more active. In contrast to rituximab or hA20, these new protein constructs lack constant region (Fc) functions, because no antibody-dependent or complement-mediated cellular cytotoxicities were observed, thus indicating that these new antibodies kill lymphoma cells exclusively by signal transduction mechanisms. Finally, studies with human lymphoma cells growing in mice showed that these new fusion proteins are very active in controlling tumor growth and increasing survival, even at very low doses (single injection of 4 micro gram).

In a statement by company President and CEO, Cynthia L. Sullivan: "These findings demonstrate that the DNL method can make multivalent fusion proteins that are stable for both in vitro and in vivo applications. More importantly, because multiple copies of binding sites are built into the final products, they are more potent than their parental proteins."

"While we have been focusing on using DNL to create more potent immunotherapy agents because of our expertise in monoclonal antibodies, the technology is versatile and also can be used to generate multifunctional binary complexes of proteins other than antibodies. This technology is particularly suitable for creating protein derivatives where conjugation or modification with non-protein groups are involved," she further commented.

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We have recently licensed our lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide. We have retained the rights for epratuzumab in oncology indications for which UCB has been granted a buy-in option. UCB has development, manufacture and commercialization rights, and is responsible for all clinical trials evaluating epratuzumab for the treatment of patients with moderate and severe lupus. At present, there is no cure for lupus and no new lupus drug has been approved in the U.S. in the last 40 years. We believe that our portfolio of intellectual property, which includes approximately 108 patents issued in the United States, and more than 250 other issued patents worldwide, protects our product candidates and technologies. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel dock and lock methodology, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. Visit our web site at http://www.immunomedics.com.

This release, in addition to historical information, may contain forward- looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

Immunomedics, Inc.
http://www.immunomedics.com
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page